Is your next doctor going to be a chatbot? The question sounds ripped from a bad sci-fi novel, but it’s rapidly becoming a legitimate concern for anyone who’s ever waited on hold for a prescription refill or dreaded a rushed annual checkup. The real story here isn’t about the dazzling potential of artificial intelligence in healthcare – we’ve been hearing that for years – it’s about how quickly, and with what minimal oversight, we’re letting algorithms step into the role of physician, and what that means for the fundamental doctor-patient relationship.
A Silicon Valley Investor’s Provocative Claim
The shift gained significant momentum last month when Robert Nelsen, a prominent biotech investor, publicly declared that AI is poised to replace doctors. Speaking at a live recording of STAT’s “Readout LOUD” podcast in San Francisco, Nelsen didn’t hedge his bets. He stated AI is already superior to “most of [his] doctors,” a claim that predictably ignited a firestorm on social media. While many dismissed it as typical Silicon Valley hyperbole, Nelsen doubled down on his prediction via X, signaling this isn’t just a thought experiment for him. This isn’t about AI assisting doctors, it’s about AI becoming the doctor. And the speed at which this is being pursued is what’s truly unsettling.
Original reporting: STAT.
Utah’s Regulatory Gamble
The most concrete manifestation of this trend is unfolding in Utah. A startup called Doctronic is piloting an “AI Doctor” – essentially a chatbot – that the state is allowing to renew prescriptions. Crucially, Utah is doing this by waiving existing regulations governing the practice of medicine. This isn’t a case of fitting a new technology into an existing framework; it’s a deliberate dismantling of safeguards. Doctronic argues, and Utah regulators appear to agree, that their AI falls outside the purview of the Food and Drug Administration (FDA). The reasoning, as reported by STAT’s Mario Aguilar, is complex and hinges on the chatbot being classified as a decision-support tool rather than a medical device. This is a semantic loophole with potentially enormous consequences.
The FDA Avoidance Strategy and Why It Matters
The FDA avoidance strategy is the key to understanding what’s happening. Typically, any software that diagnoses or treats medical conditions requires rigorous testing and approval. Doctronic is sidestepping this process by framing its chatbot as simply providing information to patients, who then make the final decision about their prescriptions – even if that “decision” is essentially rubber-stamping the AI’s recommendation. This is a dangerous blurring of lines. The average person isn’t equipped to evaluate complex medical data, and the very act of presenting a recommendation is a form of medical advice. The FDA’s silence on this matter is also telling. Are they overwhelmed by the pace of innovation? Are they hesitant to stifle a potentially beneficial technology? Or are they simply waiting to see what happens before intervening?
Beyond Renewals: The Erosion of Trust
The immediate concern is prescription renewals, but the implications extend far beyond that. If an AI can renew a prescription for, say, a blood pressure medication, what’s to stop it from diagnosing common ailments, recommending over-the-counter treatments, or even offering preventative care advice? The core of the doctor-patient relationship is trust – the belief that your physician is acting in your best interest, using their expertise and judgment to guide your care. Can an algorithm truly inspire that level of trust? And what happens when the algorithm makes a mistake? Who is liable? Doctronic’s website boasts about the AI’s ability to “personalize” care, but personalization without human oversight risks reinforcing existing biases and exacerbating health disparities. In 20 years, we may look back at this moment as the beginning of the end of personalized human care.
By 2026, expect to see a surge in similar regulatory gambits by health tech companies, targeting states with more permissive environments. The question isn’t if AI will play a larger role in healthcare, but how that role will be defined and regulated. Watch closely for the first major lawsuit stemming from an AI-driven medical error – that will be the inflection point, forcing a national conversation about the limits of algorithmic medicine and the enduring value of a human touch.
